Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Microbot Medical (MBOT) Gains from Sales and Divestitures (2016)

Microbot Medical's Gains from Sales and Divestitures history spans 4 years, with the latest figure at $194620.0 for Q3 2016.

  • For the quarter ending Q3 2016, Gains from Sales and Divestitures rose 122.42% year-over-year to $194620.0, compared with a TTM value of $194620.0 through Sep 2016, up 122.42%, and an annual FY2015 reading of $1.5 million, changed N/A over the prior year.
  • Gains from Sales and Divestitures for Q3 2016 was $194620.0 at Microbot Medical, up from $32078.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.5 million in Q4 2015, with the low at $22500.0 in Q3 2014.
  • Average Gains from Sales and Divestitures over 4 years is $408267.4, with a median of $297067.5 recorded in 2014.
  • Year-over-year, Gains from Sales and Divestitures soared 288.89% in 2015 and then tumbled 94.63% in 2016.
  • Tracing MBOT's Gains from Sales and Divestitures over 4 years: stood at $565883.0 in 2013, then skyrocketed by 50.42% to $851216.0 in 2014, then surged by 77.42% to $1.5 million in 2015, then plummeted by 87.11% to $194620.0 in 2016.
  • Per Business Quant, the three most recent readings for MBOT's Gains from Sales and Divestitures are $194620.0 (Q3 2016), $32078.0 (Q2 2016), and $217919.0 (Q1 2016).